AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 285480 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline as a vasoconstrictor additive to 2% Xylocitin at a concentration of 1:100,000
Number of subjects: 0
Study 285480 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline as a vasoconstrictor additive to 2% Xylocitin at a concentration of 1:100,000
Number of subjects: 0
Study 31013275 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAN program (Lay health supporters, E-platform, Award, and iNtegration) with mobile text messaging for medication reminders and health education
Number of subjects: 278
Study 31013275 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving community-based free-medicine program
Number of subjects: 278
Study 31013275 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAN program
Number of subjects: 278
Study 31013275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 278
Study 28521249 — intervention group
Group type: EXPERIMENTAL
Intervention: Videogame simulation
Number of subjects: 132
Study 28521249 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to the application)
Number of subjects: 132
Study 28616874 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 60
Study 23594362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C at 320 mg/kg body weight
Number of subjects: 14
Study 23594362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C at 480 mg/kg body weight
Number of subjects: 14
Study 23594362 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 14
Study 21872169 — intervention group
Group type: EXPERIMENTAL
Intervention: ContaSure Needleless System
Number of subjects: 50
Study 19576298 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 17630550 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-based therapy (peginterferon alfa-2a plus ribavirin)
Number of subjects: 853
Study 17630550 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HCV-RNA levels (<= 400,000 IU/ml vs > 400,000 IU/ml)
Number of subjects: 853
Study 17630550 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype
Number of subjects: 853
Study 17630550 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV treatment (with a protease inhibitor or non-nucleoside reverse transcriptase inhibitor)
Number of subjects: 853
Study 17630550 — intervention group
Group type: EXPERIMENTAL
Intervention: Race
Number of subjects: 853
Study 17630550 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 853
Study 14698254 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 0
Study 14698254 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal standard (IS) - diclofenac
Number of subjects: 0
Study 11264734 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐α (IFN) therapy
Number of subjects: 142
Study 11264734 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated)
Number of subjects: 142
Study 9874048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin infusion (23 patients)
Number of subjects: 43
Study 9874048 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients, no nitroglycerin)
Number of subjects: 43
Study 9874048 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 43
Study 8612437 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie plus fat restriction (CAL + FAT)
Number of subjects: 90
Study 8612437 — intervention group
Group type: COMPARATOR
Intervention: Calorie restriction (CAL)
Number of subjects: 90
Study 2474100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg)
Number of subjects: 8
Study 2474100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1029010 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid, rifampicin, ethambutol
Number of subjects: 80
Study 1029010 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid, streptomycin and p‐aminosalicylic acid
Number of subjects: 80
Study 30431501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique (group US)
Number of subjects: 74
Study 30431501 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided technique (group P)
Number of subjects: 74
Study 28729361 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib (100 mg/d)
Number of subjects: 39
Study 28729361 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/d plus placebo
Number of subjects: 39
Study 28729361 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 39
Study 28729361 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo plus Anacetrapib (100 mg/d)
Number of subjects: 39
Study 25502167 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 44
Study 25502167 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer zotarolimus-eluting stent (DP-ZES)
Number of subjects: 44
Study 25502167 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stents (BP-SES and DP-ZES)
Number of subjects: 44
Study 23274615 — intervention group
Group type: EXPERIMENTAL
Intervention: Past‐day Adults' Sedentary Time (PAST) questionnaire
Number of subjects: 90
Study 23274615 — intervention group
Group type: COMPARATOR
Intervention: activPAL sit/lie time
Number of subjects: 90
Study 20824770 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus-eluting stent (EES)
Number of subjects: 300
Study 20824770 — intervention group
Group type: COMPARATOR
Intervention: TAXUS paclitaxel-eluting stent
Number of subjects: 300
Study 19820590 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic 2000FORTE
Number of subjects: 72
Study 19820590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 16626581 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (7.8-11.0 mmol/L)
Number of subjects: 308
Study 16626581 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (≥ 11.0 mmol/L)
Number of subjects: 308
Study 15562784 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF (Group A)
Number of subjects: 61
Study 15562784 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI (Group B)
Number of subjects: 61
Study 15562784 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF (Group E)
Number of subjects: 61
Study 15562784 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF and ICSI (Group C)
Number of subjects: 61
Study 15562784 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI after failed IVF (Group D)
Number of subjects: 61
Study 11949728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecologic case-referent design
Number of subjects: 0
Study 11949728 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trial design
Number of subjects: 0
Study 9156371 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg zileuton at 7 AM
Number of subjects: 12
Study 9156371 — intervention group
Group type: COMPARATOR
Intervention: 600-mg zileuton at 11 PM
Number of subjects: 12
Study 9156371 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg zileuton four times daily for 5 days
Number of subjects: 12
Study 7663861 — intervention group
Group type: EXPERIMENTAL
Intervention: Needleless electroacupuncture
Number of subjects: 40
Study 3191758 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-protocol group
Number of subjects: 0
Study 3191758 — intervention group
Group type: COMPARATOR
Intervention: CVP-control group
Number of subjects: 0
Study 3191758 — intervention group
Group type: COMPARATOR
Intervention: PA-control group
Number of subjects: 0
Study 31196366 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning based Artificial Intelligence (AI)
Number of subjects: 200
Study 31196366 — intervention group
Group type: COMPARATOR
Intervention: Radiologists
Number of subjects: 200
Study 29191176 — intervention group
Group type: EXPERIMENTAL
Intervention: eCRF (electronic case report forms)
Number of subjects: 27
Study 29191176 — intervention group
Group type: COMPARATOR
Intervention: pCRF (paper case report forms)
Number of subjects: 27
Study 25408998 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month walking program (target 150 min/wk, moderate intensity)
Number of subjects: 44
Study 25408998 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonwalkers)
Number of subjects: 44
Study 23875741 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with tiotropium and formoterol
Number of subjects: 38
Study 23875741 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 38
Study 21750564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkles
Number of subjects: 362
Study 21750564 — intervention group
Group type: EXPERIMENTAL
Intervention: Foodlets
Number of subjects: 362
Study 21750564 — intervention group
Group type: COMPARATOR
Intervention: Drops
Number of subjects: 362
Study 18832385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher stent
Number of subjects: 130
Study 18832385 — intervention group
Group type: COMPARATOR
Intervention: Taxus stent
Number of subjects: 130
Study 16879518 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine (n = 152)
Number of subjects: 310
Study 16879518 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine (n = 155)
Number of subjects: 310
Study 14738659 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (group A) with six monthly alpha-fetoprotein (AFP) assays
Number of subjects: 5581
Study 14738659 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 5581
Study 14738659 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (group A)
Number of subjects: 5581
Study 10983746 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed social support (DS)
Number of subjects: 56
Study 10983746 — intervention group
Group type: COMPARATOR
Intervention: Natural social support (NS)
Number of subjects: 56
Study 9062523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose tablet (3 g)
Number of subjects: 12
Study 9062523 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame-polydextrose tablet (3 g)
Number of subjects: 12
Study 9062523 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsweetened polydextrose tablet (3 g)
Number of subjects: 12
Study 8340445 — intervention group
Group type: EXPERIMENTAL
Intervention: dextroamphetamine (d‐AMPH)
Number of subjects: 33
Study 8340445 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate (MPH)
Number of subjects: 33
Study 8340445 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study 3320950 — intervention group
Group type: EXPERIMENTAL
Intervention: ARA‐C + RBZ (with or without CPA)
Number of subjects: 91
Study 3320950 — intervention group
Group type: EXPERIMENTAL
Intervention: Age < 40 years
Number of subjects: 91
Study 3320950 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >= 40 years
Number of subjects: 91
Study 3320950 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction regimen with or without CPA
Number of subjects: 91
Study 3320950 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy (CNS prophylaxis and reinductions every 6 weeks for 36 months)
Number of subjects: 91
Study 29940669 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (100 mg/day for 28 days)
Number of subjects: 11
Study 29940669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 26655558 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin 100 mg/m(2) with conventional radiotherapy (cis100 + RT)
Number of subjects: 65
Study 26655558 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin 40 mg/m(2) weekly with accelerated radiotherapy (cis40 + ART)
Number of subjects: 65
Study 26655558 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Number of subjects: 65
Study 26655558 — intervention group
Group type: COMPARATOR
Intervention: cis100 + RT
Number of subjects: 65
Study 26655558 — intervention group
Group type: COMPARATOR
Intervention: cis40 + ART
Number of subjects: 65
Study 25807399 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Resuscitation (CR)
Number of subjects: 192
Study 25807399 — intervention group
Group type: COMPARATOR
Intervention: Standard Resuscitation (SR)
Number of subjects: 192
Study 24338186 — intervention group
Group type: EXPERIMENTAL
Intervention: Maixuekang Capsule (MKC) combined with routine medication
Number of subjects: 236
Study 24338186 — intervention group
Group type: COMPARATOR
Intervention: Routine medication (Control)
Number of subjects: 236
Study 21471106 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-376 120 mg every day
Number of subjects: 151
Study 21471106 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-376 240 mg every day
Number of subjects: 151
Study 21471106 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-376 240 mg twice a day
Number of subjects: 151
Study 21471106 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-376 (all doses)
Number of subjects: 151
Study 21471106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 18266872 — intervention group
Group type: EXPERIMENTAL
Intervention: Initially non‐submerged implants (group A)
Number of subjects: 84
Study 18266872 — intervention group
Group type: COMPARATOR
Intervention: Initially submerged implants (group B)
Number of subjects: 84
Study 17192453 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) curriculum; n=38
Number of subjects: 77
Study 17192453 — intervention group
Group type: COMPARATOR
Intervention: Non-evidence-based medicine (non-EBM); n=39
Number of subjects: 77
Study 12653261 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 tablets at a dose of 2 mg 3 times a week for 6 weeks
Number of subjects: 28
Study 12653261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study 11012489 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop administration of propofol/alfentanil
Number of subjects: 100
Study 11012489 — intervention group
Group type: COMPARATOR
Intervention: Manual control of propofol/alfentanil
Number of subjects: 100
Study 11012489 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop administration of isoflurane/nitrous oxide
Number of subjects: 100
Study 11012489 — intervention group
Group type: COMPARATOR
Intervention: Manual control of isoflurane/nitrous oxide
Number of subjects: 100
Study 8826539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine hydrochloride (0.9 mg/kg)
Number of subjects: 14
Study 8826539 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 14
Study 1394810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillations of Adriamycin or mitomycin C, given once a week for the first 2 weeks, once every other week for 14 weeks, once a month for 8 months, and once every 3 months for 1 year (total of 21 instillations in 2 years)
Number of subjects: 158
Study 1394810 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 158
Study 1394810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillations of Adriamycin or mitomycin C
Number of subjects: 158
Study 1394810 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with tumor progression
Number of subjects: 158
Study 1394810 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without tumor progression
Number of subjects: 158
Study 6327513 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate salt restriction (200 to 50 mmol/day) over 2 weeks
Number of subjects: 52
Study 6327513 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-sensitive subjects
Number of subjects: 52
Study 6327513 — intervention group
Group type: COMPARATOR
Intervention: Usual high sodium diet
Number of subjects: 52
Study 31446884 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma zinc ≥106.9 μg/dL
Number of subjects: 1198
Study 31446884 — intervention group
Group type: COMPARATOR
Intervention: Baseline plasma zinc <106.9 μg/dL
Number of subjects: 1198
Study 31446884 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma zinc <103.3 μg/dL
Number of subjects: 1198
Study 31446884 — intervention group
Group type: COMPARATOR
Intervention: Baseline plasma zinc ≥103.3 μg/dL
Number of subjects: 1198
Study 28423932 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-stranded cross-stitch cruciate (4-0 polyester and 4-0 braided suture)
Number of subjects: 75
Study 28423932 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-stranded double Pennington (2-0 knotless barbed suture)
Number of subjects: 75
Study 28423932 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-stranded Pennington (4-0 double-stranded braided suture)
Number of subjects: 75
Study 28423932 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-stranded modified Lim-Tsai (4-0 looped braided suture)
Number of subjects: 75
Study 28423932 — intervention group
Group type: EXPERIMENTAL
Intervention: Braided cruciate
Number of subjects: 75
Study 28423932 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed suture
Number of subjects: 75
Study 27320538 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 37
Study 27320538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 24569538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei LP-33
Number of subjects: 425
Study 24569538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study 22234519 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 166
Study 22234519 — intervention group
Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 166
Study 22234519 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 166
Study 20445015 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine (15 mg, 3 times daily; positive control)
Number of subjects: 0
Study 20445015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20445015 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (5 mg, twice daily)
Number of subjects: 0
Study 20445015 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (1 mg/d for 14 days)
Number of subjects: 0
Study 20445015 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (2 mg/d for 14 days)
Number of subjects: 0
Study 20445015 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (2 mg/d for 30 days)
Number of subjects: 0
Study 20445015 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (4 mg/d)
Number of subjects: 0
Study 20445015 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (6 mg/d)
Number of subjects: 0
Study 17608844 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:10,000 epinephrine
Number of subjects: 216
Study 17608844 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 216
Study 17608844 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted epinephrine plus normal saline
Number of subjects: 216
Study 16185377 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale‐15 screening and Montgomery‐Asberg Depression Rating Scale assessment
Number of subjects: 242
Study 16185377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing treatment for depression
Number of subjects: 242
Study 16185377 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in institutions and number of medications
Number of subjects: 242
Study 16185377 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 242
Study 12354212 — intervention group
Group type: EXPERIMENTAL
Intervention: C. albicans positive at baseline
Number of subjects: 150
Study 12354212 — intervention group
Group type: EXPERIMENTAL
Intervention: C. albicans positive post-treatment
Number of subjects: 150
Study 12354212 — intervention group
Group type: EXPERIMENTAL
Intervention: C. albicans positive at 12 months
Number of subjects: 150
Study 12354212 — intervention group
Group type: EXPERIMENTAL
Intervention: C. albicans positive at 24 months
Number of subjects: 150
Study 12354212 — intervention group
Group type: EXPERIMENTAL
Intervention: C. albicans positive at 36 months
Number of subjects: 150
Study 12354212 — intervention group
Group type: EXPERIMENTAL
Intervention: C. albicans carriage over time
Number of subjects: 150
Study 12354212 — intervention group
Group type: EXPERIMENTAL
Intervention: C. albicans carriage consistency
Number of subjects: 150
Study 12354212 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in prevalence from baseline to post-treatment
Number of subjects: 150
Study 10080203 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical debridement
Number of subjects: 278
Study 10080203 — intervention group
Group type: COMPARATOR
Intervention: Transepithelial debridement
Number of subjects: 278
Study 7480473 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for altering Positive Affect, involves completing a boring task for a specific time, with time period adjusted after starting
Number of subjects: 95
Study 2158410 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times daily)
Number of subjects: 19
Study 2158410 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (5 g three times daily)
Number of subjects: 19
Study 2158410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7341065 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 511
Study 7341065 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin Ointment
Number of subjects: 511
Study 7341065 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin Sulfate
Number of subjects: 511
Study 30628857 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Trocar Insertion (DTI)
Number of subjects: 955
Study 30628857 — intervention group
Group type: COMPARATOR
Intervention: Open Access Technique (OAT)
Number of subjects: 955
Study 28642210 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg for 1 year
Number of subjects: 1560
Study 28642210 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75mg for 1 year
Number of subjects: 1560
Study 28642210 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg + PPI for 1 year
Number of subjects: 1560